Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review

Overview

Journal Clin Cosmet Investig Dermatol

Publisher Dove Medical Press

Date 2025 Feb 4

PMID 39901963

Authors

Giuseppe Lauletta

Luca Potestio

Cataldo Patruno

Mario DE Lucia

Maddalena Napolitano

Affiliations

Soon will be listed here.

Abstract

Introduction: Atopic dermatitis (AD) and pruritic skin disorders are increasingly recognized in cancer patients. The management of these conditions in patients with a history or with concomitant cancer presents unique challenges, as traditional systemic therapies may pose risks due to their immunosuppressive effects. In recent years, biologic agents such as dupilumab and tralokinumab have emerged as promising treatments for AD, offering targeted modulation of the immune response with potentially fewer systemic side effects. This article aims to review the current evidence on the safety and efficacy of dupilumab and tralokinumab in treating AD and pruritus among cancer survivors, addressing the potential benefits and considerations for this unique patient population.

Methods: A comprehensive analysis of the current medical literature was performed on the PubMed, Ovid, Scopus, Embase, and Cochrane Library databases until December 15, 2024. In conducting this narrative review, Medical Subject Headings (MeSH) terms and medical terminology related to clinical trials and real-life studies were employed, focusing on the pharmacological agents dupilumab, and tralokinumab.

Discussion: Patients with active or past cancer are typically excluded from clinical trials of new medications, complicating the evaluation of cancer progression or recurrence risks in these patients setting. The potential use of biologic drugs like dupilumab and tralokinumab in oncological patients marks a significant breakthrough for treating conditions such as eczema and pruritus, which are common in this patient group. Although there are no explicit contraindications for using dupilumab and tralokinumab in patients with active cancer or a history of malignancy, there is no definitive guidance on their use in such cases. Real-world data is emerging, facilitated by collaboration between dermatologists and oncologists, supporting the effectiveness and safety of dupilumab and tralokinumab for managing AD in cancer patients. Nonetheless, larger studies with longer follow-up periods and dedicated pharmacovigilance programs are needed to substantiate these findings.

References

Qiu Y, Ali K, Lou H, Shan J, Wu L . Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin's Lymphoma. Acta Derm Venereol. 2021; 102:adv00625. PMC: 9593481. DOI: 10.2340/actadv.v101.224. View

Dequidt L, Franck N, Sanchez-Pena P, Dalle S, Adamski H, Boulinguez S . Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database. Br J Dermatol. 2019; 181(3):616-618. DOI: 10.1111/bjd.17834. View

Bieber T, Thyssen J, Reich K, Simpson E, Katoh N, Torrelo A . Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2020; 35(2):476-485. DOI: 10.1111/jdv.16948. View

Simpson E, Bieber T, Guttman-Yassky E, Beck L, Blauvelt A, Cork M . Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016; 375(24):2335-2348. DOI: 10.1056/NEJMoa1610020. View

Chang P, Huang S, Chang P, Yu Y . Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications. J Dermatol. 2021; 48(11):1631-1639. DOI: 10.1111/1346-8138.16116. View

Zackheim H, Koo J, LeBoit P, McCalmont T, Bowman P, Kashani-Sabet M . Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine. J Am Acad Dermatol. 2002; 47(1):155-7. DOI: 10.1067/mjd.2002.120571. View

Ensslin C, Rosen A, Wu S, Lacouture M . Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013; 69(5):708-720. PMC: 4181350. DOI: 10.1016/j.jaad.2013.06.038. View

Kandiel A, Fraser A, Korelitz B, Brensinger C, Lewis J . Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54(8):1121-5. PMC: 1774897. DOI: 10.1136/gut.2004.049460. View

Braddock M, Hanania N, Sharafkhaneh A, Colice G, Carlsson M . Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review. Drug Saf. 2018; 41(5):489-509. PMC: 5938313. DOI: 10.1007/s40264-017-0636-9. View

10.

Tanczosova M, Hugo J, Gkalpakiotis S . Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer. J Clin Med. 2023; 12(3). PMC: 9918040. DOI: 10.3390/jcm12031191. View

11.

Kuo A, Gu S, Stoll J, Moy A, Dusza S, Gordon A . Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer. 2023; 11(6). PMC: 10255229. DOI: 10.1136/jitc-2023-007324. View

12.

Potestio L, Patruno C, Dastoli S, Brescia C, Napolitano M . Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations. J Asthma Allergy. 2024; 17:791-799. PMC: 11330743. DOI: 10.2147/JAA.S474411. View

13.

Napolitano M, Fabbrocini G, Neri I, Stingeni L, Boccaletti V, Piccolo V . Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study. Paediatr Drugs. 2022; 24(6):671-678. PMC: 9417930. DOI: 10.1007/s40272-022-00531-0. View

14.

Bugelski P, Volk A, Walker M, Krayer J, Martin P, Descotes J . Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int J Toxicol. 2010; 29(5):435-66. DOI: 10.1177/1091581810374654. View

15.

Simpson E, Merola J, Silverberg J, Reich K, Warren R, Staumont-Salle D . Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022; 187(6):888-899. PMC: 10091996. DOI: 10.1111/bjd.21867. View

16.

Napolitano M, Fabbrocini G, Potestio L, Fontanella G, Picone V, Bennardo L . A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis. Dermatol Ther. 2022; 35(8):e15588. DOI: 10.1111/dth.15588. View

17.

Svoboda S, Johnson N, Phillips M . Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors. Skin Therapy Lett. 2020; 25(4):6-11. View

18.

Macagno N, Mastorino L, Siliquini N, Santaniello U, Gelato F, Cavaliere G . Safety of dupilumab in patients with cancer. J Eur Acad Dermatol Venereol. 2024; 38(9):e764-e766. DOI: 10.1111/jdv.19873. View

19.

Francuzik W, Alexiou A, Worm M . Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opin Drug Saf. 2021; 20(9):997-1004. DOI: 10.1080/14740338.2021.1939673. View

20.

Adam D, Gooderham M, Beecker J, Hong C, Jack C, Jain V . Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol. 2023; 37(6):1135-1148. DOI: 10.1111/jdv.18922. View